Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China

被引:36
作者
Li, Fei [1 ]
Li, Pu [1 ]
Zhang, Rongyan [1 ]
Yang, Ganping [1 ]
Ji, Dexiang [1 ]
Huang, Xianbao [1 ]
Xu, Qian [1 ]
Wei, Yanlin [1 ]
Rao, Jia [1 ]
Huang, Ruibing [1 ]
Chen, Guoan [1 ]
机构
[1] Nanchang Univ, Dept Hematol, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China
关键词
Lymphoma-associated hemophagocytic; syndrome (LAHS); Hemophagocytic syndrome ( HPS); Clinical features; T-CELL LYMPHOMA; EPSTEIN-BARR-VIRUS; DEFICIENCY; IMMUNODEFICIENCY; HLH-94; CD27;
D O I
10.1007/s12032-014-0902-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To identify the clinical features of lymphomaassociated hemophagocytic syndrome (LAHS), we retrospectively analyzed the clinical characteristics, laboratory findings and survival data of 16 LAHS patients from 69 adult hemophagocytic syndrome (HPS) patients. The results showed that the most common clinical manifestations and laboratory parameters were fever (100 %), ferritin >= 500 g/L (100 %), peripheral cytopenia in two or more lineages (100 %), fibrinogen (Fbg)< 1.5 g/L (93.8 %) and splenomegaly (81.3 %) in LAHS patients. The percentages of patients with Fbg < 1.5 g/L, PLT < 40 x 10 (9)/L and LDH >= 1,000 U/L in the LAHS group were significantly higher than those in non-LAHS patients (P = 0.010, 0.000, and 0.001, respectively). Survival analysis showed that HLH patients with rheumatological reasons had better prognosis (OS; median not reached), followed by patients in the infection group (350 days) and those with unexplained causes (140 days). LAHS had the worst prognosis (only 37 days). The symptoms of LAHS patients are usually confused with other HPS. Patients with LAHS had higher probabilities to have Fbg < 1.5 g/L, PLT < 40 x 10 (9)/L, LDH >= 1,000 U/L and poor prognosis, so early diagnosis and systemic treatments are required.
引用
收藏
页数:7
相关论文
共 28 条
[1]  
Arico M, 1996, LEUKEMIA, V10, P197
[2]   The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications [J].
Campo, Elias ;
Swerdlow, Steven H. ;
Harris, Nancy L. ;
Pileri, Stefano ;
Stein, Harald ;
Jaffe, Elaine S. .
BLOOD, 2011, 117 (19) :5019-5032
[3]   Hemophagocytic Lymphohistiocytosis: Advances in Pathophysiology, Diagnosis, and Treatment [J].
Chandrakasan, Shanmuganathan ;
Filipovich, Alexandra H. .
JOURNAL OF PEDIATRICS, 2013, 163 (05) :1253-1259
[4]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[5]  
FALINI B, 1990, BLOOD, V75, P434
[6]   FAMILIAL HAEMOPHAGOCYTIC RETICULOSIS [J].
FARQUHAR, JW ;
CLAIREAUX, AE .
ARCHIVES OF DISEASE IN CHILDHOOD, 1952, 27 (136) :519-525
[7]   Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases [J].
Fukaya, S. ;
Yasuda, S. ;
Hashimoto, T. ;
Oku, K. ;
Kataoka, H. ;
Horita, T. ;
Atsumi, T. ;
Koike, T. .
RHEUMATOLOGY, 2008, 47 (11) :1686-1691
[8]   HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis [J].
Henter, Jan-Inge ;
Horne, AnnaCarin ;
Arico, Maurizio ;
Egeler, R. Maarten ;
Filipovich, Alexandra H. ;
Imashuku, Shinsaku ;
Ladisch, Stephan ;
McClain, Ken ;
Webb, David ;
Winiarski, Jacek ;
Janka, Gritta .
PEDIATRIC BLOOD & CANCER, 2007, 48 (02) :124-131
[9]   INCIDENCE IN SWEDEN AND CLINICAL-FEATURES OF FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS [J].
HENTER, JI ;
ELINDER, G ;
SODER, O ;
OST, A .
ACTA PAEDIATRICA SCANDINAVICA, 1991, 80 (04) :428-435
[10]  
Henter JI, 1997, MED PEDIATR ONCOL, V28, P342, DOI 10.1002/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO